New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
12:00 EDTGLMDGalmed rises 24.2%
Galmed is up 24.2%, or $3.15, to $16.15
News For GLMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
08:27 EDTGLMDGalmed's aramchol for hepatitis shows positive IIa results
Galmed Pharmaceuticals' Chief Medical Officer, Dr. Maya Halpern, will present a poster at the 1st European Fatty Liver Conference held in Maastricht on March the 5th and 6th. Halpern will present the importance of testing endothelial function, or the function of the lining of blood vessels, as an early marker of atherosclerosis, or the hardening of the arteries. Dr. Halpern stated, "in our Phase IIa study, aramchol demonstrated, in a dose-dependent manner, trends of improvement in endothelial function. In addition to liver fat content and histological signs of Non-Alcoholic Steato-Hepatitis, our Phase IIb study, ARREST, is examining endothelial function using the validated EndoPAT technology developed by Itamar Medical. Confirmation of aramchol's effect on the improvement of endothelial function, if found, could position aramchol as a highly differentiated option in the treatment of patients with NASH."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use